Managed Access Programs for CTL019, Tisagenlecleucel

Available (expanded access)

Conditions studied: Lymphoma, Leukemia, Off-label Indications

In brief

The purpose of this registration is to list Managed Access Programs (MAPs) related to CTL019, Tisagenlecleucel

Key facts

Study ID

NCT03601442

Run by

Novartis Pharmaceuticals

Last updated by the study team

2026-04-23

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• An independent request was received from a licensed physician. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.
• The patient is not eligible or able to enrol in a clinical trial or continue participation in such trial.
• There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
• The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable).
• Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program.
• Managed Access provision is allowed per local laws/regulations.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.